Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... PRC Clinical, the Clinical Trial ... Regenerative Medicine (ARM). The ARM counts more than ... commercialization of transformational treatments and cures for patients ... CRO focused in Clinical Trial Management, has developed ... research working with sponsors in the United States ...
(Date:5/25/2015)... The 2015 Market Research Report on ... and in-depth study on the current state of ... a focus on the Chinese situation. Major companies ... Linde Industrial Gas, Basf, Air Products, Air Liquide, ... Longsheng Group, Juhua Group, Wandali Gas, Unid(Jiangsu) Chemical, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Charm ... U.S. Department of Agriculture (USDA), Grain Inspection, Packers ... year contract to Charm Sciences to monitor aflatoxin ... Test (water-based) and ROSA FAST Aflatoxin Quantitative Test ... Quantitative Test uses Water Extraction Technology to ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Seventh Wave ... safety and efficacy of pharmaceutical products and medical devices, ... Heights, MO 63043, a 50,000 sq. ft. building more ... to enable strategic growth. Facility renovations will begin immediately ... new space will occur in September. , “We ...
Breaking Biology Technology:PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 2PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 3Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3
... team of U.S., Israeli and German scientists used computational ... role in human cell division and to identify more ... pattern of activation in cancer cells., Malignant cells have ... in cell cycle gene activation in normal and malignant ...
... ... Patients, CAMBRIDGE, ... ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ),announced today that ... and commercialize mipomersen, Isis, lipid-lowering,treatment for high risk cardiovascular patients that ...
... Wins for Industry Leadership, JOPLIN, Mo., Jan. ... announced its Medical Power group has received,Battery Power ... received honors in the Industry Leadership category for ... battery., The Innova Award recognizes companies that ...
Cached Biology Technology:International team identifies 480 genes that control human cell division 2International team identifies 480 genes that control human cell division 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 2Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 4Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 5Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 6Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 7EaglePicher Technologies Receives Battery Power Products and Technology's First Annual Innova Award 2
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... 10, 2011The mega-mergers of 2009 did not continue into 2010. ... price tag of more than $40 billion, only last year,s ... of reported deals conducted by Genetic Engineering & Biotechnology News ... the year, sanofi-aventis, move to buy Genzyme, is still being ...
... reports that several herbicides used on corn also have ... Miscanthus), a potential bioenergy feedstock. "No herbicides are ... biomass," said Eric Anderson, an instructor of bioenergy for ... of Illinois. "Our research shows that several herbicides used ...
... 20,000 to 30,000 genes (the number is hotly contested), but ... proteins. It,s the protein molecules that domost of the work ... from the Greek prota, meaning "of primary importance." Proteins ... of usually fold spontaneously into what is called their "native ...
Cached Biology News:GEN reports on biotech acquisition deals in 2010 that topped $1 billion 2Miscanthus has a fighting chance against weeds 2New method takes snapshots of proteins as they fold 2New method takes snapshots of proteins as they fold 3New method takes snapshots of proteins as they fold 4New method takes snapshots of proteins as they fold 5
...
... T7 Phage Capture Plate is a 96-well ELISA-compatible ... the T7 Tail Fiber Monoclonal Antibody is immobilized ... The antibody specifically recognizes the tail fiber protein ... has a capacity of 10 9 phage ...
... TRAPeze RT Telomerase Detection Kit ... vitro assay for the fluorometric ... of telomerase activity. It incorporates ... assay and adds the ability ...
... The expertise that made the original Gene Pulser ... system available has been applied in the Gene ... The modular design of the Gene Pulser II ... accessory that has the widest range of settings ...
Biology Products: